PURPOSE: To perform a multicentre intercomparison study of treatment concepts for MRI assisted brachytherapy of cervix cancer based on recommendations of the Gynaecological GEC-ESTRO Working Group. METHODS: Each participating centre (IGR Paris, University Hospital Leuven, Medical University of Vienna) contributed data of one patient with comparable clinical features. GTV, High Risk CTV (HR CTV), Intermediate Risk CTV (IR CTV) and organ walls of bladder, rectum and sigmoid colon were delineated at the time of each brachytherapy fraction on axial MR images with the applicator in place. Dose-volume histograms were calculated to evaluate doses to tumour, target volumes and organs at risk. Dose values were biologically normalised to equivalent doses in 2 Gy fractions (EQD(2), equivalent to 50 cGy/h low dose rate) applying the linear-quadratic model. RESULTS: Total doses to point A from external beam therapy plus brachytherapy ranged from 85 to 91 Gy and were close to the dose covering 90% of HR CTV (D90=85-87 Gy). D90 of IR CTV was within 69-73 Gy. Doses to organs at risk were comparable. CONCLUSIONS: This study indicates the feasibility of the GEC-ESTRO recommendations. Despite different treatment concepts, biologically normalised total doses to tumour, target volumes and organs at risk were comparable.
PURPOSE: To perform a multicentre intercomparison study of treatment concepts for MRI assisted brachytherapy of cervix cancer based on recommendations of the Gynaecological GEC-ESTRO Working Group. METHODS: Each participating centre (IGR Paris, University Hospital Leuven, Medical University of Vienna) contributed data of one patient with comparable clinical features. GTV, High Risk CTV (HR CTV), Intermediate Risk CTV (IR CTV) and organ walls of bladder, rectum and sigmoid colon were delineated at the time of each brachytherapy fraction on axial MR images with the applicator in place. Dose-volume histograms were calculated to evaluate doses to tumour, target volumes and organs at risk. Dose values were biologically normalised to equivalent doses in 2 Gy fractions (EQD(2), equivalent to 50 cGy/h low dose rate) applying the linear-quadratic model. RESULTS: Total doses to point A from external beam therapy plus brachytherapy ranged from 85 to 91 Gy and were close to the dose covering 90% of HR CTV (D90=85-87 Gy). D90 of IR CTV was within 69-73 Gy. Doses to organs at risk were comparable. CONCLUSIONS: This study indicates the feasibility of the GEC-ESTRO recommendations. Despite different treatment concepts, biologically normalised total doses to tumour, target volumes and organs at risk were comparable.
Authors: José Luis Guinot; José Pérez-Calatayud; Silvia Rodríguez; Alejandro Tormo; Vincente Crispán; Juan Carlos Menéndez Journal: Clin Transl Oncol Date: 2010-03 Impact factor: 3.405
Authors: M Dolezel; K Odrazka; J Vanasek; T Kohlova; T Kroulik; K Kudelka; D Spitzer; M Mrklovsky; M Tichy; J Zizka; L Jalcova Journal: Br J Radiol Date: 2011-09 Impact factor: 3.039
Authors: P Georg; A Boni; A Ghabuous; G Goldner; M P Schmid; D Georg; R Pötter; W Dörr Journal: Strahlenther Onkol Date: 2013-05-25 Impact factor: 3.621
Authors: Richard Pötter; Petra Georg; Johannes C A Dimopoulos; Magdalena Grimm; Daniel Berger; Nicole Nesvacil; Dietmar Georg; Maximilian P Schmid; Alexander Reinthaller; Alina Sturdza; Christian Kirisits Journal: Radiother Oncol Date: 2011-08-05 Impact factor: 6.280
Authors: Primoz Petric; Robert Hudej; Peter Rogelj; Mateja Blas; Barbara Segedin; Helena Barbara Zobec Logar; Johannes Carl Athanasios Dimopoulos Journal: Radiol Oncol Date: 2012-04-11 Impact factor: 2.991